The Asia Pacific systemic aspergillosis and systemic candidasis market is projected to reach US$ 2,030.54 million by 2027 from US$ 1,437.77 million in 2019; it is estimated to grow at a CAGR of 4.5% from 2020 to 2027.
The growth of the systemic aspergillosis and systemic candidasis market is primarily attributed to rise in prevalence of fungal diseases and hospital acquired fungal infections. Moreover, the COVID-19 pandemic has highly affected countries in Asia Pacific, further affecting the systemic aspergillosis and systemic candidasis market in the region.
Fungal systemic infections are common in patients with weakened immune system, including immunosuppressed people and acquired immunodeficiency syndrome (AIDS) patients. Systemic signs consolidates indications such as apnea, guaiac-positive stools, abdominal distension, hyperglycemia, leukemoid reaction, hypotension, and others. The treatment of systemic candidasis and aspergillosis need parenteral antifungal therapy. These conditions may result in permanent neurodevelopmental deficits in long-term survivors; further, they are associated with high mortality rates. Fungus Candida auris causes a severe global health threat. In several Asia-Pacific countries, the fungus causes severe illness in hospitalized patients as the colonization of the fungus may continue for long time; the fungus can persist on surfaces in healthcare environments, which may result in the infection spread between patients in the facilities. It can colonize skin, axilla, and rectum, among other anatomical sites. As per a study published by the Oxford University in February 2017, India has a higher prevalence of C. auris infection; the number of cases was higher among the public sector hospitals in north India. The factors such as extended stays in ICUs, respiratory illness, vascular surgery, medical intervention, and antifungal exposure are the major risk factors contributing to the high incidence of C. auris infection among the patients exhibiting lower morbidity levels. Furthermore, the countermeasures to limit fungal infections in intensive care units (ICUs) continuously reported, with a tendency to an endemic pattern. This reflects the ability of C. auris to persist in a clinical environment, enabling its transmission within acute care settings. Thus, the rising hospital-acquired fungal infection is creating demand for systemic aspergillosis and systemic candidasis preventing drugs.
In 2019, the systemic oral azoles accounted for the highest share and is expected to grow faster during the forecast period as due to its advancementin systemic antifungal therapy. For instance, fluconazole has the most attractive pharmacologic (pharmacokinetics and pharmacodynamic) profile, including the capacity to produce high concentrations of active drug in cerebrospinal fluid and urine.
A few major primary and secondary sources associated with this report on the systemic aspergillosis and systemic candidasis market are, the US Food and Drug Administration (FDA), National Library of Medicine National Institutes of Health, and International Society for Human and Animal Mycology.